LiDCO Group Plc Japan registration &appointment of new distributor (0556C)

TIDMLID

RNS Number : 0556C

LiDCO Group Plc

17 January 2018

LiDCO Group Plc

("LiDCO" or the "Company")

Japan registration for new LiDCOunity v2 & appointment of new distributor

LiDCO (AIM: LID), the hemodynamic monitoring company, announces that it has been granted registration in Japan for its latest product, the LiDCOunity v2 and will showcase it at the 45th Annual Meeting of the Japanese Society of Intensive Care Medicine, which will be held in Chiba, Japan from 21-23 February 2018.

At the same time, LiDCO is pleased to announce that it has signed an exclusive three year agreement with Merit Medical Japan to distribute LiDCO products in Japan. Merit Medical Japan is a subsidiary of Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology, oncology, critical care and endoscopy.

Japan is currently the second largest market in the world for hemodynamic monitoring. The Company estimates that there are approximately 680,000 high-risk surgical patients per annum in Japan. The Company's technology already enjoys attractive in-market reimbursement for both its minimally invasive and non-invasive technologies. It believes the new monitor in the hands of the right strategic partner is key to gaining greater market share.

More information about LiDCOunity v2 can be found on the Company's relaunched website www.lidco.com

Commenting on the registration and distribution agreement, Matt Sassone, Chief Executive Officer of LiDCO, said: "This is an exciting development for our business in Japan. Launching our latest monitor and partnering with Merit, a leading provider of critical care products in Japan, will increase our prospects as we look to gain greater market share in this important market."

For further information, please contact:

 
 LiDCO Group Plc                          www.lidco.com 
 Matt Sassone (CEO)            Tel: [phone] 
 
 finnCap                       Tel: [phone] 
 Geoff Nash / Emily Watts 
  (Corporate Finance) 
 Stephen Norcross (Corporate 
  Broking) 
 
 Walbrook PR Ltd                  Tel: [phone] or 
                                   [e-mail] 
 Paul McManus                        Mob: [phone] 
 Lianne Cawthorne                    Mob: [phone] 
 

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, originally developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring. Version 2 of this software is only available on a new slim widescreen monitor and includes the optional high usage program software in selected markets.

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness.

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

-- early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

-- quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BIS(TM') )* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

*BIS(TM) and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's headquarters are in London and its shares are traded on AIM.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCQQLFFVFFZBBK

(END) Dow Jones Newswires

January 17, 2018 02:00 ET (07:00 GMT)